Cargando…

PB1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS

Detalles Bibliográficos
Autores principales:	Abdennebi, Naima, Boukhemia, Fateh, Harieche, Farida, Amer, Nacera Ait, Tensaout, Farida, Moussaoui, Hanane, Akhrouf, Sabrina, Benakli, Malek, Hamladji, Rose-Marie, Ahmed-Nacer, Redhouane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429963/ http://dx.doi.org/10.1097/01.HS9.0000974684.85689.dc

Ejemplares similares

PB2467: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 39 PATIENTS WITH NON-HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP IN A SINGLE CENTRE
por: Louar, Fouzia, et al.
Publicado: (2023)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA
por: Imene, Semoud, et al.
Publicado: (2023)

PB1967: ROLE OF CYTOKINES IN MULTIPLE MYELOMA: IL-1RN AND IL-4 VNTR POLYMORPHISMS
por: Serin, I., et al.
Publicado: (2022)

PB1803: EARLY DEATH IN ACUTE PROMYELOCYTIC LEUKEMIA: DEFINING HIGH RISK PATIENTS
por: `Ben Salah, M., et al.
Publicado: (2022)

PB1802: ACUTE PROMYELOCYTIC LEUKEMIA AND THROMBOSIS: HOW TO IDENTIFY THE HIGH-RISK PATIENTS?
por: `Ben Salah, M., et al.
Publicado: (2022)

PB2639: CHANGES IN PLATELETS IN CHRONIC LIVER DISEASES
por: Nuriddinova, Nodira
Publicado: (2023)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY
por: LI, Ziyu, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
por: Bektaş, M., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB2086: CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION
por: Otasevic, V., et al.
Publicado: (2022)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

PB2445: THE ROLE OF MEDITERRANEAN DIET IN CHRONIC GVHD: A PILOT STUDY
por: Brambilla, Giulia, et al.
Publicado: (2023)

PB1906: IS THERE A PLACE FOR IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA CHRONIC PHASE: REAL LIFE DATA FROM UNIVERSITY CENTER AFTER LONG PERIOD OF FOLLOW-UP
por: Lekovic, D., et al.
Publicado: (2022)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hijiya, N., et al.
Publicado: (2022)

PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
por: Hijiya, Nobuko, et al.
Publicado: (2023)

PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT
por: Musteata, V.
Publicado: (2022)

PB1870: COVID - 19 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: HOSPITAL MORALITY PREDICTORS
por: Kochneva, O., et al.
Publicado: (2022)

PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN.
por: Haidary, A. M., et al.
Publicado: (2022)

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?
por: Parbutt, Catherine, et al.
Publicado: (2023)

PB2298: CHRONIC HEPATITIS B VIRAL ACTIVITY IS AN INDEPENDENT PROGNOSTIC FACTOR OF LYMPHOMA
por: Lee, Ho Sup, et al.
Publicado: (2023)

PB1916: DETECTION OF AUTOANTIBODIES TO NEUTROPHIL AND ERYTHROCYTE ANTIGENS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISEASES
por: Irina, Krobinets, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
por: Qi, Feiyang, et al.
Publicado: (2023)

PB1928: ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE MOLECULAR ERA
por: Zhang, T.
Publicado: (2022)

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

PB1920: CLINICOHEMATOLIGICAL CHARACTERISTICS AND CYTOGENETIC PROFILE OF CHRONIC MYELOMONOCYTIC LEUKEMIA; AN EXPERIENCE FROM PAKISTAN
por: ANWAR, N., et al.
Publicado: (2022)

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

PB2259: MONOCYTE’S INVOLVEMENT IN INFLAMMATORY RESPONSE IN COVID-19 INFECTION IN CHRONIC RENAL DISEASE
por: Bumbea, V., et al.
Publicado: (2022)

PB1855: LACK OF MUTATIONS IN TNFRSF13B (TACI) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Giannakoulas, N., et al.
Publicado: (2022)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9m67o1tgshj9fs5utmq0j7362